Source:http://linkedlifedata.com/resource/pubmed/id/16333937
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
11
|
| pubmed:dateCreated |
2005-12-7
|
| pubmed:abstractText |
The WHO- and IUATLD-recommended protocol for rifampicin (RMP) bioequivalence utilises 20-22 volunteers and 8 h, whereas the requirement of other regulatory authorities is 12 volunteers with a 24 h sampling schedule. Differing sampling size and time requirements may change the outcome of RMP bioequivalence.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Nov
|
| pubmed:issn |
1027-3719
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
9
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1273-80
|
| pubmed:dateRevised |
2006-6-12
|
| pubmed:meshHeading | |
| pubmed:year |
2005
|
| pubmed:articleTitle |
Minimum sample size and sampling time requirements for assessment of rifampicin bioequivalence from FDC formulations.
|
| pubmed:affiliation |
Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Mohali, Punjab, India.
|
| pubmed:publicationType |
Journal Article
|